Dietary flavanoids cut risk of heart disease

6 May 2007

A study published in the April edition of the American Journal of Clinical Nutrition found that flavanoids, a type of plant-derived antioxidant, may help lower the risk of heart disease. In the investigation, researchers evaluated the diets of more than 34,000 women, looking at their total flavonoid intake, the types of flavonoids they were consuming and what foods were contributing to their intake. They then looked at those women who consumed the most flavonoids and assessed how this affected their risk of developing heart disease, as compared to women who did not get significant flavonoid content in their diet.

The results showed that certain flavonoids from dietary sources have the potential to lower the risk of heart disease up to 22%. The most beneficial foods included green tea, red wine, berries, cocoa, bran, apples and pears, as well as less well documented flavanoid sources like almonds, parsley, coffee, beans and onions.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight